These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3457608)

  • 41. Combined differentiating therapy for myelodysplastic syndromes: a phase II study.
    Ferrero D; Bruno B; Pregno P; Stefani S; Larizza E; Ciravegna G; Luraschi A; Vietti-Ramus G; Schinco P; Bazzan M; Gallo E; Pileri A
    Leuk Res; 1996 Oct; 20(10):867-76. PubMed ID: 8960111
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Low dose all-trans retinoic acid and androgen therapy for patients with myelodysplastic syndrome].
    Guan M; Chen SC; Li RS; Ge CW; Zhu HL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Dec; 12(6):774-8. PubMed ID: 15631659
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial.
    Negrin RS; Haeuber DH; Nagler A; Olds LC; Donlon T; Souza LM; Greenberg PL
    Ann Intern Med; 1989 Jun; 110(12):976-84. PubMed ID: 2471429
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study.
    Hofmann WK; Kell WJ; Fenaux P; Castaigne S; Ganser A; Chomienne C; Burnett R; Kowal C; Hoelzer D; Burnett AK
    Leukemia; 2000 Sep; 14(9):1583-8. PubMed ID: 10995004
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
    Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
    Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Myeloid surface antigen abnormalities in myelodysplasia: relation to prognosis and modification by 13-cis retinoic acid.
    Clark RE; Smith SA; Jacobs A
    J Clin Pathol; 1987 Jun; 40(6):652-6. PubMed ID: 3475292
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia.
    Miller WH; Jakubowski A; Tong WP; Miller VA; Rigas JR; Benedetti F; Gill GM; Truglia JA; Ulm E; Shirley M
    Blood; 1995 Jun; 85(11):3021-7. PubMed ID: 7756637
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of differentiation-inducing agents in the myelodysplastic syndrome and acute non-lymphocytic leukemia.
    Hoffman SJ; Robinson WA
    Am J Hematol; 1988 Jun; 28(2):124-7. PubMed ID: 3293438
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
    Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
    Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes.
    Ganser A; Seipelt G; Verbeek W; Ottmann OG; Maurer A; Kolbe K; Hess U; Elsner S; Reutzel R; Wörmann B
    Leukemia; 1994 Mar; 8(3):369-75. PubMed ID: 7510354
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of 13 cis-retinoic acid in the remission induction of a patient with acute promyelocytic leukemia.
    Fontana JA; Rogers JS; Durham JP
    Cancer; 1986 Jan; 57(2):209-17. PubMed ID: 3455835
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proof of differentiative mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis.
    Elliott S; Taylor K; White S; Rodwell R; Marlton P; Meagher D; Wiley J; Taylor D; Wright S; Timms P
    Blood; 1992 Apr; 79(8):1916-9. PubMed ID: 1562718
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination of low-dose cytarabine and 13-cis retinoic acid in the treatment of myelodysplastic syndromes.
    Ho AD; Martin H; Knauf W; Reichardt P; Trümper L; Hunstein W
    Leuk Res; 1987; 11(11):1041-4. PubMed ID: 3320577
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dexamethasone and retinoic acid differentially regulate growth and differentiation in an immortalised human clonal bone marrow stromal cell line with osteoblastic characteristics.
    Ogston N; Harrison AJ; Cheung HF; Ashton BA; Hampson G
    Steroids; 2002 Oct; 67(11):895-906. PubMed ID: 12234625
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Eosinophilia in myelodysplastic syndrome with a (12;21)(q23;q22) translocation.
    Kobayashi H; Kitano K; Shimodaira S; Ishida F; Saito H; Sonoyama M; Enokihara H; Furuta S
    Cancer Genet Cytogenet; 1993 Jul; 68(2):95-8. PubMed ID: 8353811
    [TBL] [Abstract][Full Text] [Related]  

  • 56. GCSF augments post-progenitor proliferation in serum-free cultures of myelodysplastic marrow while ATRA enhances maturation.
    Truran L; Baines P; Hoy T; Burnett AK
    Leuk Res; 1998 Mar; 22(3):241-8. PubMed ID: 9619915
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cytogenetic studies in 32 patients with myelodysplastic syndrome: insights to specific chromosomal abnormalities and prognosis.
    Taniwaki M; Horiike S; Inazawa J; Nishida K; Misawa S; Takino T; Abe T
    Jpn J Clin Oncol; 1987 Jun; 17(2):141-50. PubMed ID: 3613138
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor.
    Hofmann WK; Ganser A; Seipelt G; Ottmann OG; Zander C; Geissler G; Hoffmann K; Höffken K; Fischer JT; Isele G; Hoelzer D
    Ann Hematol; 1999 Mar; 78(3):125-30. PubMed ID: 10211754
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia.
    Maciejewski JP; Risitano A; Sloand EM; Nunez O; Young NS
    Blood; 2002 May; 99(9):3129-35. PubMed ID: 11964274
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.
    Lübbert M; Wijermans P; Kunzmann R; Verhoef G; Bosly A; Ravoet C; Andre M; Ferrant A
    Br J Haematol; 2001 Aug; 114(2):349-57. PubMed ID: 11529854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.